[go: up one dir, main page]

CL2019003557A1 - Anticuerpos anti-trkb. - Google Patents

Anticuerpos anti-trkb.

Info

Publication number
CL2019003557A1
CL2019003557A1 CL2019003557A CL2019003557A CL2019003557A1 CL 2019003557 A1 CL2019003557 A1 CL 2019003557A1 CL 2019003557 A CL2019003557 A CL 2019003557A CL 2019003557 A CL2019003557 A CL 2019003557A CL 2019003557 A1 CL2019003557 A1 CL 2019003557A1
Authority
CL
Chile
Prior art keywords
trkb antibodies
trkb
antibodies
therapeutic
compositions
Prior art date
Application number
CL2019003557A
Other languages
English (en)
Inventor
Haiguang Xiao
Vladimir Voynov
Holger Rosenbrock
Remko Alexander Bakker
Rolf Herrmann
Sebastian Bandholtz
Peter Michael Benz
Michael Dziegelewski
Lore Florin
Cynthia Hess Kenny
Sarah Low
Sanjaya Singh
Heiko Friedrich Stahl
Sathyadevi Venkataramani
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2019003557A1 publication Critical patent/CL2019003557A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS AGONISTAS ANTI-TRKB NOVEDOSOS Y MÉTODOS TERAPÉUTICOS Y DE DIAGNÓSTICO Y COMPOSICIONES PARA SU USO.
CL2019003557A 2017-06-09 2019-12-05 Anticuerpos anti-trkb. CL2019003557A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17175122 2017-06-09

Publications (1)

Publication Number Publication Date
CL2019003557A1 true CL2019003557A1 (es) 2020-05-04

Family

ID=59034551

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003557A CL2019003557A1 (es) 2017-06-09 2019-12-05 Anticuerpos anti-trkb.

Country Status (22)

Country Link
US (3) US10793634B2 (es)
EP (1) EP3635004A1 (es)
JP (2) JP7267208B2 (es)
KR (1) KR20200017421A (es)
CN (1) CN110719916B (es)
AR (1) AR112602A1 (es)
AU (1) AU2018279184B2 (es)
BR (1) BR112019023742A2 (es)
CA (1) CA3063965A1 (es)
CL (1) CL2019003557A1 (es)
CO (1) CO2019013718A2 (es)
EA (1) EA201992883A1 (es)
IL (1) IL271067B2 (es)
MA (1) MA49257A (es)
MX (1) MX2019014714A (es)
MY (1) MY202315A (es)
PE (1) PE20200173A1 (es)
PH (1) PH12019502694A1 (es)
SG (1) SG11201911814UA (es)
TW (2) TW202342100A (es)
UA (1) UA127967C2 (es)
WO (1) WO2018224630A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110691790A (zh) * 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
AU2021322137A1 (en) 2020-08-07 2023-01-19 Boehringer Ingelheim International Gmbh Soluble NPY2 receptor agonists
WO2022084354A1 (en) * 2020-10-21 2022-04-28 Boehringer Ingelheim International Gmbh Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF
WO2025062271A1 (en) * 2023-09-19 2025-03-27 Signorile Pietro Giulio Antibodies against endometriosis
CN119841947A (zh) * 2024-12-17 2025-04-18 河南农业大学 十二指肠贾第虫cwp2蛋白的单克隆抗体及配对单克隆抗体及应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
BRPI0610938A2 (pt) * 2005-06-06 2010-08-03 Wyeth Corp anticorpos monoclonais anti-trkb e usos dos mesmos
US20100150914A1 (en) * 2006-11-09 2010-06-17 Irm Llc Agonist trkb antibodies and uses thereof
MX2009006794A (es) 2006-12-20 2009-07-02 Rinat Neuroscience Corp Agonistas del receptor tirosina quinasa b para el tratamiento de trastornos autoinmunes.
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
JP2011501760A (ja) * 2007-10-23 2011-01-13 ノバルティス アーゲー 呼吸器疾患の処置のためのｔｒｋｂ抗体の使用
MX2010007841A (es) 2008-01-17 2010-09-28 Irm Llc Anticuerpos anti-trkb mejorados.
EA021284B1 (ru) * 2008-02-04 2015-05-29 Лей Лайн Дженомикс С.П.А. Антитела и их производные
CN102159215B (zh) * 2008-07-28 2013-07-17 爱默蕾大学 使用TrkB激动剂治疗各种病症
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011103667A1 (en) * 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
CN103108633B (zh) * 2010-06-09 2016-01-27 爱默蕾大学 TrkB激动剂及其用途
WO2012027821A1 (en) 2010-09-03 2012-03-08 The Royal Institution For The Advancement Of Learning / Mcgill University A trkc receptor agonist antibody to treat neurodegenerative and motor neuron diseases
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
US10392438B2 (en) 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
AU2016298307A1 (en) 2015-07-28 2018-02-15 Otonomy, Inc. TrkB or TrkC agonist compositions and methods for the treatment of OTIC conditions
JP7039468B2 (ja) 2015-11-17 2022-03-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 神経およびその他の障害の処置のための結合アゴニスト
CN121181700A (zh) 2017-11-30 2025-12-23 瑞泽恩制药公司 抗trkb单克隆抗体及其使用方法

Also Published As

Publication number Publication date
JP2023093621A (ja) 2023-07-04
UA127967C2 (uk) 2024-02-28
TW201920271A (zh) 2019-06-01
US10793634B2 (en) 2020-10-06
EA201992883A1 (ru) 2020-05-08
US20180355046A1 (en) 2018-12-13
PE20200173A1 (es) 2020-01-24
AU2018279184A1 (en) 2019-11-21
CO2019013718A2 (es) 2020-01-17
AR112602A1 (es) 2019-11-20
TWI808086B (zh) 2023-07-11
IL271067B1 (en) 2024-02-01
JP7267208B2 (ja) 2023-05-01
KR20200017421A (ko) 2020-02-18
MY202315A (en) 2024-04-23
SG11201911814UA (en) 2020-01-30
WO2018224630A1 (en) 2018-12-13
US20240101689A1 (en) 2024-03-28
NZ758651A (en) 2024-11-29
EP3635004A1 (en) 2020-04-15
CA3063965A1 (en) 2018-12-13
TW202342100A (zh) 2023-11-01
JP2020522270A (ja) 2020-07-30
JP7505084B2 (ja) 2024-06-24
MX2019014714A (es) 2020-02-07
IL271067A (en) 2020-01-30
CN110719916A (zh) 2020-01-21
CN110719916B (zh) 2024-05-31
MA49257A (fr) 2020-04-15
AU2018279184B2 (en) 2024-08-01
US11866501B2 (en) 2024-01-09
US20200399378A1 (en) 2020-12-24
PH12019502694A1 (en) 2020-07-13
BR112019023742A2 (pt) 2020-06-09
IL271067B2 (en) 2024-06-01

Similar Documents

Publication Publication Date Title
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2019003557A1 (es) Anticuerpos anti-trkb.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CL2016001871A1 (es) Anticuerpos humanos para pd-1
BR112016014731A2 (pt) Anticorpos anti-baff
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
BR112016029860A2 (pt) conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112021011124A2 (pt) Anelossomos e métodos de uso
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
BR112019020412A2 (pt) composições e métodos para detectar câncer de pulmão
CR20180110A (es) Libobactina para uso en el tratamiento de la mastitis bovina
CU20180079A7 (es) Inhibidores de la proteína quinasa 1 que interactúa con el receptor
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
UY37009A (es) Formulaciones granuladas de giberelina